Bio-identical Hormones Replacement Therapy Market

Bio-identical Hormones Replacement Therapy Market Outlook

At present, the global bio-identical hormones replacement market value accounts for USD 36,059.24 Million in 2022. This market is expected to grow with a CAGR of 5.1% for the forecast duration of 2022-2032. The valuation of the bio-identical hormones replacement segment is expected to surpass the value of USD 59,298.50 Million by end of 2032.

Report Attributes	Details
Bio-identical Hormones Market size (2022 A)	USD 36,059.24 Million
Base Year for Estimation	2022
Forecast duration for this research	2022-2032
Forecasted Market value (2032 F)	USD 59,298.50 Million
Global Market Growth rate (2022-2032 E)	CAGR 5.1%
Key Companies Profiled	SottoPelle Biostation Neuva Aesthetics Advantage Pharmaceuticals, Inc. Defy Medical Full Life Wellness Center BioTE Medical TherapeuticsMD BodyLogicMD RevitaLife Aesthetics & Wellness US Compounding

What are the Factors that Favor the growth of Bio-identical Hormones Replacement?

Bio-identical hormone replacement process involves plant-based estrogens that are used to resemble hormones produced by the human body. In recent years, bio-identical hormone replacement has noticed rising demand as there is an increase in hormone-related health issues.

The hormonal issues rise with the declining levels of hormones with rising age. These changes are visible in weight gain, lower body energy, and lack of sleep.

Maintaining the hormonal balance in the body drives the growth of hormone replacement therapies. The rising lifestyle stress and increasing cancer cases globally are likely to have a stake in the demand for hormonal replacement treatment in the future. There is rising awareness about treating hormonal deficiencies, which is a key factor for growth in the market in recent years.

Hormonal replacement therapy is widely gaining acceptance in women patients as they are effective in treating menopause, unusual weight gain, vaginal dryness, and mood swings. The rising awareness among women regarding health issues has a positive impact on the growth of the bio-identical hormone replacement therapy market. With more women becoming financially stable, this market is expected to continue growing in the forecast duration.

Safety of Bioidentical Hormones Puts the Players away from the Game

The US food and drug administration (FDA) passes the bio-identical hormones after testing for safety. These hormone tests have been sustained through the strict compliance standards by FDA. However, considering the risks and side effects, experts suggest choosing FDA-approved hormones after the advice of a healthcare assistant.

Players Optimize the Efficiency of Bio-identical Hormones for Better Sales

The results of bio-identical hormone treatment are likely to differ from person to person depending on the body considerations and health history of a person. The consultation of a healthcare person essentially has a crucial role in spreading the right awareness about the possible impacts and benefits associated with bio-identical hormone treatment among people. Bio-identical hormone replacement therapy is suggested by experts over traditional hormone replacement treatments.

Risks Associated with Bio-identical Hormone Replacement Therapy that is likely to Affect Market Growth

There is considerable risk carried with these therapies, including side effects on the body and heart. There are incidences of heart conditions found in patients after hormone replacement, including stroke and attacks. As per the research of Cleveland Clinic, There is a risk of blood clots and gallbladder diseases associated with hormone therapies.

The compounded bio-identical hormones are associated with the risks as they are not approved by FDA and not suggested by health experts due to their long-term side effects. However, these side effects are more in the initial stages as the body is new to the inserted hormones, and with time body gets adjusted to the new levels of hormones.

High cost and potential side effects are major restraints faced by this market. The lower healthcare expenditure of poor and developing economies further hinders the penetration of the bio-identical hormone replacement therapy market. Rising demand for menopausal hormone therapy is likely to result in a supply shortage, increasing the struggle for players in the market.

Segment wise analysis

Oral insertion of hormones is preferred for ease of administration

Based on the way to administrate, the oral insertion of hormones has the largest market share in 2022. This is expected to grow in the forecast duration. Oral therapies are mostly preferred for the ease of administration associated with them. However, oral hormone replacement therapy has disadvantages, such as the need for daily dosing. These doses are relatively high compared with doses used parenterally.

There are variations in intestinal absorption and an increase in plasma triglyceride levels leading to alteration in hepatic proteins. Moreover, there is a concern about the elevation of triglyceride levels with oral estragon, an important risk factor for cardiovascular disease.

Parenteral administration is associated with a new matrix transdermal alcohol-free and causes lower skin reactions. This method does not affect the plasma profile, unlike the oral route. There is a reduced risk of cardiovascular diseases in parenteral ways owing to controlled trials.

The menopause segment is estimated to grow the demand for hormone replacement therapies.

Based on the indication, the menopausal segment is projected to grow at the fastest rate due to a global hormonal imbalance surge among women. The menopause can be more severe if hypothyroidism is not treated well. Treating thyroid symptoms is essential to manage menopause, where hormonal replacement is a decisive factor.

There is steady growth in growth hormone deficiencies owing to genetic defects and severe brain injuries, as there are no clear causes rectified in many cases. This segment is expected to open opportunities for research in the forecast duration.

North America is the leading region in the bio-identical hormone therapy market

As per the women’s health across the nation(SWAN) survey, around 80% of women in the USA have reported vasomotor symptoms that indicate the early start of menopause affecting their reproductive abilities. This opens the scope for the growth in demand for quality hormone replacement therapies in this region in the forecast period.

The rise in demand for these therapies is also attributed to the rise in the financial abilities of individuals, increased health awareness, rising health expenditure, and increasing women’s workforce participation in the region. Available healthcare support, access to treatments, and education available across people are reasons for rising demand in the North American region.

Europe remains the second largest market owing to higher per-person income and commendable penetration of health care infrastructure.

The Asia Pacific regions are also expected to drive the growth of bio-identical hormone markets in the future due to progression in government initiatives and changing social-cultural perspectives towards women’s health issues. India and China are anticipated to become major players in forecast durations owing to their rising health expenditure and growth in the healthcare sector.

China is expected to mark dynamic progress in upcoming years due to its initiative to cut the prevalence rate. The amendment of Chinese health policies is likely to favor demand for bio-identical hormone replacement therapies in the forecast duration.

Strategies by Bio-Identical Hormones Replacement Therapy Market Player

The players in the global hormone replacement therapy market experience higher competition as the industry is driven by key companies that focus on gaining maximum share and applying market competencies. These players rely on collaborations, strategic partnerships, and acquisitions. Standards of services, and assistance before and post therapies are also decisive factors for industry players to maintain customer trust and edge in markets.

• In October 2018, TherapeuticsMD received FDA approval for its TX-001HR: BIJUVA™ capsules for the treatment of moderate to severe vasomotor symptoms of menopause. According to the company, it is the first and only bio-identical hormone therapy approved by the FDA which uses a combination of estradiol and progesterone.
• The Biostation has recently launched educational eBooks for uncovering root causes and solutions for making customers aware of their health. These guides are designed to give information and treatment solutions leading to customer trust.

Bio-identical Hormones Replacement Therapy Market: Segmentation

The global bio-identical hormones replacement therapy market has been segmented :

• By Administration

  • Oral
  • Parenteral
  • Other

• By Segment

  • Menopause
  • Growth hormone deficiency
  • Other

• By Type

  • Estrogens
  • Progesterone
  • Testosterone
  • Others

• By Product Type

  • Tablets and capsules
  • Creams and gels
  • Injectable
  • Patches and Implants
  • Others

• By End User

  • Hospitals
  • Clinics
  • Research and academics
  • Others

• By Region

  • North America
  • Latin America
  • Europe
  • Japan
  • APEJ
  • MEA